Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients

Japanese Journal of Ophthalmology

Volumn 47, Issue 2, 2003, Pages 199-207

  Araie, Makoto ^a   Azuma, Ikuo ^b   Kitazawa, Yoshiaki ^c  

^a UNIVERSITY OF TOKYO   (Japan)

^b OSAKA MEDICAL COLLEGE   (Japan)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Betaxolol; Clinical study; Glaucoma; Timolol; Visual field

Indexed keywords

BETAXOLOL; TIMOLOL;

ADULT; AGED; ARTICLE; BLEPHARITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DYSPNEA; ERYTHEMA; FEMALE; HEART ATRIUM FLUTTER; HUMAN; INTRAOCULAR PRESSURE; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; TOPICAL TREATMENT; VISUAL FIELD;

EID: 0038639117     PISSN: 00215155     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-5155(02)00665-2     Document Type: Article

References (52)

1. Grant W.M., Burke J.F. Why do some people go blind from glaucoma? Ophthalmology. 89:1982;991-998.
2. Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthalmol. 65(Suppl):1987;27-29.
3. Mao L.K., Stewart W.C., Shields M.B. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 111:1991;51-55.
4. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 126:1998;487-497.
5. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 126:1998;498-505.
6. Bergeå B., Bodin L., Svedbergh B. Impact of intraocular pressure regulation on visual fields in open-angle glaucoma. Ophthalmology. 106:1999;997-1005.
7. The AGIS Investigators The advanced glaucoma intervention study (AGIS). 7. The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol. 130:2000;429-440.
8. Schulzer M., Mikelberg F.S., Drance S.M. Some observations on the relation between intraocular pressure reduction and the progression of glaucomatous visual loss. Br J Ophthalmol. 71:1987;486-488.
9. Schulzer M., Drance S.M., Carter C.J., Brooks D.E., Douglas G.R., Lau W. Biostatistical evidence for two distinct chronic open angle glaucoma populations. Br J Ophthalmol. 74:1990;196-200.
10. Anderson D.R. The damage caused by pressure. XLVI Edward Jackson Memorial Lecture. Am J Ophthalmol. 108:1989;485-495.
11. Flammer J. The vascular concept of glaucoma. Surv Ophthalmol. 38(Suppl):1994;3-6.
12. Fechtner R.D., Weinreb R.N. Mechanisms of optic nerve damage in primary open angle glaucoma. Surv Ophthalmol. 39:1994;23-42.
13. Flammer J., Guthauser U., Mahler F. Do ocular vasospasms help cause low tension glaucoma? Doc Ophthalmol Proc Ser. 49:1987;397-399.
14. 2+-antagonist on visual field in low-tension glaucoma. Graefes Arch Clin Exp Ophthalmol. 227:1989;408-412.
15. Netland P.A., Chaturvedi N., Dreyer E.B. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol. 115:1993;608-613.
16. Sawada A., Kitazawa Y., Yamamoto T., Okabe I., Ichien K. Prevention of visual field defect progression with brovincamine in eyes with normal-tension glaucoma. Ophthalmology. 103:1996;283-288.
17. Harris A., Evans D.W., Cantor L.B., Martin B. Hemodynamic and visual function effects of oral nifedipine in patients with normal-tension glaucoma. Am J Ophthalmol. 124:1997;296-302.
18. Piltz J.R., Bose S., Lanchoney D. The effect of nimodipine, a centrally active calcium antagonist, on visual function and macular blood flow in patients with normal-tension glaucoma and control subjects. J Glaucoma. 7:1998;336-342.
19. Ishida K., Yamamoto T., Kitazawa Y. Clinical factors associated with progression of normal-tension glaucoma. J Glaucoma. 7:1998;372-377.
20. Koseki N., Araie M., Yamagami J., Shirato S., Yamamoto S. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. J Glaucoma. 8:1999;117-123.
21. Messmer C., Flammer J., Stümpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol. 112:1991;678-681.
22. Collignon-Brach J. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol. 38(Suppl):1994;149-155.
23. Kaiser H.J., Flammer J., Stümpfig D., Hendrickson P. Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Surv Ophthalmol. 38(Suppl):1994;156-160.
24. Tasindi E., Talu H. Differential effect of betaxolol and timolol on the progression of glaucomatous visual field loss. Drance S.M. Vascular risk factors and neuroprotection in glaucoma - update 1996. 1997;227-234 Kugler, Amsterdam/New York.
25. Drance S.M. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma. 7:1998;247-252.
26. Mason R.P., Kosoko O., Wilson M.R.et al. National Survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. Part I. Prevalence findings. Ophthalmology. 96:1989;1363-1368.
27. Shiose Y., Kitazawa Y., Tsukahara S.et al. Epidemiology of glaucoma in Japan - A nationwide glaucoma survey. Jpn J Ophthalmol. 35:1991;133-155.
28. Klein B.E., Klein R., Sponsel W.E.et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology. 99:1992;1499-1504.
29. Coffey M., Reidy A., Wormald R., Xian W.X., Wright L., Courtney P. Prevalence of glaucoma in the west of Ireland. Br J Ophthalmol. 77:1993;17-21.
30. Mitchell P., Smith W., Attebo K., Healey P.R. Prevalence of open-angle glaucoma in Australia. Ophthalmology. 103:1996;1661-1669.
31. Dielemans I., Vingerling J.R., Wolfs R.C.W., de Jon P.T.V.M. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands. The Rotterdam Study. Ophthalmology. 101:1994;1851-1855.
32. Leske M.C., Connell A.M.S., Schachat A.P., Hyman L., the Barbados Eye Study Group The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol. 112:1994;821-829.
33. Buhrmann R.R., Quigley H.A., Barron Y., West S.K., Oliva M.S., Mmbaga B.B.O. Prevalence of glaucoma in a rural east African population. Invest Ophthalmol Vis Sci. 41:2000;40-48.
34. Capliori J. Automated perimetry in glaucoma. Am J Ophthalmol. 111:1991;235-239.
35. Suzuki Y., Araie M., Ohashi Y. Sectorization of the central 30° visual field in glaucoma. Ophthalmology. 100:1993;69-75.
36. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics. 38:1982;963-974.
37. Strahlman E., Tipping R., Vogel R., International Dorzolamide Study Group A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxo-lol. Arch Ophthalmol. 113:1995;1009-1016.
38. Kitazawa Y., Azuma I., Araie M. Clinical evaluation of betaxo-lol hydrochloride in the treatment of primary open angle glaucoma and ocular hypertension - multi-center double-masked study in comparison with timolol. Rinsho Hyoka. 17:1989;243-274. (in Japanese).
39. Zeiter J.H., Shin D.H., Baek N.H. Visual field defects in diabetic patients with primary open-angle glaucoma. Am J Ophthalmol. 111:1991;581-584.
40. Zeiter J.H., Shin D.H. Diabetes in primary open-angle glaucoma patients with inferior visual field defects. Graefes Arch Clin Exp Ophthalmol. 232:1994;205-210.
41. Repka M.X., Savino P.J., Schatz N.J., Sergott R.C. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol. 96:1983;478-483.
42. Gramer E., Althaus G. Quantifizierung und Progredienz des Gesichtsfeldschadens bei Glaukom ohne Hochdruck, Glaucoma simplex und Pigmentglaukom. Klin Monatsbl Augenheilkd. 191:1987;184-198.
43. Zeiter J.H., Shin D.H., Juzych M.S., Jarvi T.S., Spoor T.C., Zwas F. Visual field defects in patients with normal-tension glaucoma and patients with high-tension glaucoma. Am J Ophthalmol. 114:1992;758-763.
44. Gupta A., Chen H.C., Rassam S.M.B., Kohner E.M. Effect of betaxolol on the retinal circulation in eyes with ocular hypertension. a pilot study Eye. 8:1994;668-671.
45. Harris A., Spaeth G.L., Sergott R.C., Katz L.J., Cantor L.B., Martin B.J. Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. Am J Ophthalmol. 120:1995;168-175.
46. Yoshida A., Ogasawara H., Fujio N.et al. Comparison of short- and long- term effects of betaxolol and timolol on human retinal circulation. Eye. 12:1998;848-853.
47. Tamaki Y., Araie M., Tomita K., Nagahara M. Effect of topical betaxolol on tissue circulation in the human optic nerve head. J Ocul Pharmacol Ther. 15:1999;313-321.
48. Yu D.-Y., Su E.-N., Cringle S.J., Alder V.A., Yu P.K. Effect of betaxolol, timolol and nimodipine on human and pig retinal arterioles. Exp Eye Res. 67:1998;73-81.
49. Osborne N.N., Cazevieille C., Carvalho A.L., Larsen A.K., DeSantis L. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 751:1997;113-123.
50. Osborne N.N., DeSantis L., Bae J.H.et al. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res. 69:1999;331-342.
51. Hirooka K., Kelly M.E.M., Baldridge W.H., Barnes S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res. 70:2000;611-621.
52. Gross R.L., Hensley S.H., Wu S.M. Retinal ganglion cell dysfunction induced by hypoxia and glutamate. Potential neuroprotective effects of β-blockers Surv Ophthalmol. 43(Suppl):1999;162-170.